

## Accepted Manuscript

Title: Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: A systematic review and meta-analysis

Authors: Yongxian Su, Jiawei Wu, Yu Gu


PII: S1572-1000(17)30538-0  
DOI: <https://doi.org/10.1016/j.pdpdt.2018.05.002>  
Reference: PDPDT 1161

To appear in: *Photodiagnosis and Photodynamic Therapy*

Received date: 5-12-2017  
Revised date: 8-4-2018  
Accepted date: 4-5-2018

Please cite this article as: Su Y, Wu J, Gu Y, Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: A systematic review and meta-analysis, *Photodiagnosis and Photodynamic Therapy* (2018), <https://doi.org/10.1016/j.pdpdt.2018.05.002>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



# Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: A systematic review and meta-analysis

## Author List

Yongxian Su<sup>a</sup>, Jiawei Wu<sup>a</sup>, Yu Gu<sup>a</sup>

<sup>a</sup> The Second Affiliated Hospital of Southern Medical University, Guangzhou 510000, China

## Highlights

- Photodynamic therapy combined with ranibizumab has no inferiority compared with monotherapy.
- Combination therapy could decrease the injections of ranibizumab, compared with ranibizumab monotherapy.
- Combination therapy had a better stability of vision than monotherapy in one year, although the vision it maintained was not as good as that with monotherapy.
- The baseline BCVA has a great influence on the number of ranibizumab injections.
- BCVA improvement with combination therapy was inferior to that with ranibizumab monotherapy over 12 months of follow-up and its proportions of patients gaining more than 15 letters was smaller than that in monotherapy.

Download English Version:

<https://daneshyari.com/en/article/8765335>

Download Persian Version:

<https://daneshyari.com/article/8765335>

[Daneshyari.com](https://daneshyari.com)